Tarsus Pharmaceuticals, Inc.
TARS
Rank in Stocks
#4580
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Share Price
$70.82
Last synced: 2026-10-21
Market Cap
$3.31B
Change (1 day)
-0.30%
Change (1 year)
3.08%
Country
US
Trade Tarsus Pharmaceuticals, Inc. (TARS)
Category
Healthcare
Stock price history for Tarsus Pharmaceuticals, Inc. (TARS)
Highest end of day price: $72.26 on 2026-10-01
Lowest end of day price: $21.51 on 2020-10-01
Lowest end of day price: $21.51 on 2020-10-01
Stock price history of Tarsus Pharmaceuticals, Inc. from 2020 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.95 | -3.70% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
